Signed and dated informed consent, and able to comply with the study procedures and any locally required authorization.
Male or female aged ≥ 18 years.
Advanced disease not curable by available therapies and requires systemic therapy.
Histologically confirmed diagnosis of eligible cancer type.
Must have tumor tissue available for biomarker testing.
Measurable disease (Part 1) and measurable disease per RECIST (Part2)
Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
Life expectancy \> 3 months as assessed by the Investigator.
Adequate organ function (bone marrow, hepatic, renal function and coagulation).
All toxicities (except alopecia) from prior cancer treatments or procedures must have resolved to ≤Grade 1 or returned to baseline levels prior to enrollment.
You may not be if
Pregnant or breastfeeding females and women of childbearing potential or males unwilling to comply with contraception requirements.
Known active or symptomatic CNS metastases, carcinomatous meningitis, leptomeningeal disease or a history of spinal cord compression
Active malignancy within 2 years of study enrollment
Prior radiation within 2 weeks of start of therapy.
Systemic cancer treatments, monoclonal antibody-directed therapies, other investigational agents within 4 weeks before enrollment, or \<5 half-lives since completion of previous investigational therapy, whichever is shorter.
Uncontrolled intercurrent illness.
Immunocompromised subjects with increased risk of opportunistic infections or history of opportunistic infection in the last 12 months.
Known active or chronic hepatitis B or active hepatitis C virus (HCV) infection.
Subjects with corrected QT interval \>470 msec based on averaged triplicate electrocardiogram (ECG) readings at the Screening Visit using the QT interval corrected for heart rate using Fridericia's method (QTcF).
Clareo Health | Study of STP938 (Dencatistat) in Advanced Solid Tumours
